Revenue ($USD): $2,802,249,000
R&D spend: $256,889,000.00
Employees: 8,200
Fiscal year end: 12/31/22
CEO: Norman Schwartz
Bio-Rad will be an interesting company to watch as the demand for the COVID-19-related diagnostics that boosted business over the past few years continues to fall. The company this yearinitiated a $500 million share repurchase program.–SW